Logotype for SBC Medical Group Holdings Incorporated

SBC Medical Group Holdings (SBC) Q2 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for SBC Medical Group Holdings Incorporated

Q2 2026 earnings summary

26 Aug, 2026

Executive summary

  • Q2 2026 revenue rose 13–13.4% year-over-year to $49–$49.2 million, with net income attributable to shareholders up 335% to $10.7–$11 million, driven by AI-enabled service enhancements, higher management services revenue, and network expansion.

  • Adjusted EBITDA increased 32% year-over-year to $20 million, with margin expanding to 41%.

  • Strategic focus on multi-brand aesthetic dermatology, non-aesthetic healthcare as a second growth engine, global expansion (notably in the U.S. and Southeast Asia), and AI-driven cost structure reform.

  • Completed structural reforms in 2025, entering a phase of re-accelerated growth with profit growth outpacing revenue growth.

  • Expanded business base and enhanced support functions, notably through AI, driving operational efficiency and customer experience.

Financial highlights

  • Q2 2026 total revenues: $49–$49.2 million (+13–13.4% YoY); net income: $10.7–$11 million (+335% YoY); adjusted EBITDA: $20 million (+32% YoY); adjusted EBITDA margin: 41%.

  • Net income margin for Q2 2026: 21.7–22% (+16pt YoY); basic EPS: $0.10 (+400% YoY).

  • Gross profit for Q2 2026: $36 million (+19.9% YoY); gross margin: 73.1%.

  • Cash and cash equivalents as of June 30, 2026: $184–$184.3 million; capital ratio: 64.9%.

  • Year-to-date clinic revenue rose 11%, same clinic revenue up 6%, and average spend per visit increased 9% to $287.

Outlook and guidance

  • AI-enabled platform and revised service agreements expected to drive sustainable growth in clinic locations, average fee per clinic, and service breadth, with $15 million in annualized management service revenue increases anticipated.

  • Continued strong growth in customer volume and unit price expected, with further improvements anticipated in Q3 and Q4.

  • Targeting 1,000 clinics by 2035, with a shift toward greater non-aesthetic healthcare revenue and entry into the Longevity market.

  • U.S. and Southeast Asia strategies focus on asset-light expansion and leveraging local partnerships.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more